The abstract is read at the publisher; the summary is JClub's.
In adults with Rome IV irritable bowel syndrome, a microbiome-guided personalized diet maintained IBS Severity Scoring System improvements at 6 and 12 months, unlike low-FODMAP.
- Why it matters: The durability of low-FODMAP diet benefits and whether microbiome-guided personalization sustains long-term symptom and microbiome changes in IBS is unclear.
- What they did: In a multicenter open-label randomized trial with blinded outcome assessment, participants completed a 6-week personalized diet or standard low-FODMAP diet, then were followed at 6 and 12 months; outcomes used IBS-SSS, IBS-QOL, HADS, and 16S rRNA gut profiling.
- The result: At 12 months, IBS-SSS responder rates were higher with personalized diet than low-FODMAP (62.5% vs 34.5%; absolute risk difference +28.0%, 95% CI 4.2–47.7; Fisher p = 0.029), with more favorable IBS-QOL and HADS trajectories and sustained Shannon alpha-diversity gains.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.